• SpCas9 mRNA: Identity, Mechanism, and Evidence Limits

  2026-10-16

  APExBIO describes SpCas9 mRNA (ARCA, 5mCTP, ψUTP) as a modified messenger RNA encoding Streptococcus pyogenes Cas9 for guide-directed genome editing in eukaryotic research systems. The documented properties support an intended molecular role, but the supplied information provides no identity-matched study data on translation, DNA cleavage, editing efficiency, specificity, cellular responses, or applicability across models.

• Mdivi-1 and CIH: Reading a Lung Apoptosis Study

  2026-10-16

  A recent mouse study linked chronic intermittent hypoxia with pulmonary mitochondrial injury, apoptosis-associated signaling, gut microbiota disruption, and altered lipid metabolites. Mdivi-1 attenuated several of these changes, but the evidence supports a pharmacologically consistent pathway model rather than definitive proof that the gut microbiota or DRP1-mediated fission caused the lung injury.

• SpCas9 mRNA: Documented Identity and Scope

  2026-10-15

  APExBIO describes SKU R1006 as ARCA-capped, polyadenylated SpCas9 mRNA incorporating 5mCTP and ψUTP, with two nuclear localization signals and a C-terminal HA tag. The product information supports a conceptual role in guide-directed CRISPR-Cas9 genome editing and DNA double-strand break induction in eukaryotic systems, but it provides no identity-matched research data establishing translation, editing efficiency, specificity, stability, immune response, or performance in a particular model.

• PAD4-IN-2 TFA: Evidence and Mechanistic Scope

  2026-10-15

  APExBIO describes PAD4-IN-2 TFA, also identified as Compound 5i TFA, as a meta-phenylboronic acid-modified PAD4 inhibitor with reported effects on histone H3 citrullination, NET formation, tumor-cell behavior, and tumor immune context. Because no identity-matched primary paper is available, the article distinguishes catalog-reported findings from independently established evidence and defines the product’s applicability boundaries.

• SpCas9 mRNA: Mechanism and Evidence Boundaries

  2026-10-14

  APExBIO describes R1006 as ARCA-capped, polyadenylated SpCas9 mRNA containing 5mCTP and ψUTP, with nuclear-localization signals and a C-terminal HA tag. Its documented role is to provide Cas9 protein for guide-RNA-directed DNA cleavage, but no identity-matched study establishes product-specific editing performance, safety, or applicability across eukaryotic systems.

• SpCas9 mRNA: Evidence, Context and Limits

  2026-10-14

  SpCas9 mRNA is described by APExBIO as a modified messenger RNA encoding Streptococcus pyogenes Cas9 for guide-directed genome editing. The supplied evidence supports a conceptual discussion of CRISPR-Cas9 genome editing and plant grafting research, but it does not establish product performance, editing efficiency, or applicability in any particular organism or tissue.

• SNORA38B and Immune Evasion in NSCLC

  2026-10-13

  Zhuo et al. present preclinical evidence that the snoRNA SNORA38B is associated with aggressive non-small cell lung cancer and may influence tumor immunity through an E2F1–GAB2/AKT/mTOR signaling axis. The findings support a candidate mechanism and therapeutic hypothesis, but remain limited to cell-based and mouse models.

• Aneuploidy, CIN, and the Limits of CRISPR Inference

  2026-10-13

  Modi and Taylor’s chapter presents a literature-based framework for understanding how aneuploidy arises, how it differs from chromosomal instability, and why its effects vary across cancer and normal tissues. It does not test SpCas9 mRNA or establish conclusions about any specific genome-editing product, cell type, or clinical application.

• RNA Pol II Loss and Programmed Cell Death

  2026-10-12

  Harper et al. report that RNA polymerase II inhibition can trigger apoptosis through loss of hypophosphorylated RNA Pol IIA, rather than simply through depletion of transcriptional output. The study introduces the Pol II degradation-dependent apoptotic response (PDAR), while leaving the breadth of its relevance across tissues, therapies and disease settings to further validation.

• What the 2025 tRNA Study Actually Shows

  2026-10-12

  Li, Baranwal and Maerkl report a conceptual advance toward self-regenerating cell-free biochemistry: a PURE transcription–translation system that produces all 21 tRNAs needed for decoding formylmethionine and the 20 standard amino acids while sustaining protein expression. The work supports feasibility of in situ tRNA supply, but it does not demonstrate a fully self-regenerating synthetic cell or complete regeneration of the PURE system.

• Lamotrigine and BBB Evidence: A Better Read

  2026-10-10

  Lamotrigine research benefits from separating sodium-channel pharmacology from blood-brain barrier exposure evidence. This article interprets a 2025 surrogate BBB study through the lenses of permeability, efflux, lysosomal trapping, and translational relevance.

• O-GlcNAcylation Rewires Glycolysis in Bone Formation

  2026-10-09

  The 2024 study by You and colleagues identifies O-GlcNAcylation as a metabolic and signaling bridge linking Wnt3a activity to osteoblastogenesis. Its central mechanistic finding is that Wnt3a-dependent O-GlcNAcylation stabilizes PDK1 at Ser174, promoting aerobic glycolysis and supporting bone formation and fracture healing.

• Low-Dose Cadmium, STAT3, and Lymphangiogenesis

  2026-10-09

  A 2024 study links low-dose cadmium exposure to enhanced lymphangiogenesis through a STAT3–VEGFR3 signaling axis in corneal injury and lymphatic endothelial models. Its cross-model evidence expands environmental toxicology beyond vascular injury alone, while the findings remain limited by model specificity, dose interpretation, and the pharmacological nature of pathway inhibition.

• Atorvastatin, Ferroptosis, and HCC Research Evidence

  2026-10-08

  Atorvastatin is an HMG-CoA reductase inhibitor with established relevance to cholesterol biology and emerging preclinical interest in hepatocellular carcinoma. This overview examines a 2025 study linking atorvastatin to ferroptosis, separates computational associations from experimental findings, and outlines the evidence limits that prevent direct clinical conclusions.

• TMRE Mitochondrial Membrane Potential Assay

  2026-10-08

  The TMRE mitochondrial membrane potential assay kit converts changes in ΔΨm into a red-fluorescence readout. It is useful for mitochondrial function analysis and mitochondrial depolarization measurement, but the signal does not independently prove ATP failure, apoptosis, or necrosis.

8585 records 1/573 page Next 12345 下5页 Last page